americanpharmaceuticalreviewJune 30, 2021
Tag: AstraZeneca , Susan Galbraith , executive vice president
AstraZeneca has appointed Dr. Susan Galbraith to lead Oncology Research & Development. Her appointment follows the passing of José Baselga earlier this year. She will join the Company’s Senior Executive Team and report to Chief Executive Officer, Pascal Soriot.
Susan previously led early-stage Oncology R&D, overseeing the successful progression of seven programs into Phase III trials, with four new medicines now approved in countries around the world. During this time, she played a pivotal role in the evolution of AstraZeneca’s Oncology strategy, supporting pioneering research, embracing cutting-edge technologies and forging successful partnerships to transform productivity and scientific output.
Pascal Soriot, CEO, said: “Susan is an outstanding oncologist with a track record of delivering breakthrough science. Over the past decade at AstraZeneca, she has developed new medicines that have transformed care and improved the lives of patients around the world. She is also an exceptional leader who, together with her high-performing team, will continue to rapidly advance our exciting Oncology pipeline and execute the strategy that Susan helped to devise with José Baselga. Susan’s experience, energy, and passion for investing in the next generation of scientists will be invaluable to AstraZeneca’s next chapter of growth.”
Dr. Susan Galbraith, Executive Vice President, Oncology R&D, said: “I am honored to take on this position as we continue our work to one day cure cancer. This ambition drives our bold strategy and pulls us together as a team so that we can realize the potential of our Oncology medicines, accelerate the delivery of the next wave of science, and make an even bigger difference to patients around the world. I look forward to continuing to work with the outstanding team here at AstraZeneca and our partners to advance our plans and achieve great outcomes for patients and our company.”
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: